Xu; Xuenong
Patent Applications and Registrations
Patent applications and USPTO patent grants for Xu; Xuenong.The latest application filed is for "preparation method of cobimetinib".
- Xu; Xuenong - Suzhou CN
- Xu; Xuenong - Jiangsu CN
| Patent | Date |
|---|---|
| Preparation method of cobimetinib Grant 10,407,403 - Xu Sept | 2019-09-10 |
| Method for preparing nilotinib intermediate Grant 10,392,351 - Xu , et al. A | 2019-08-27 |
| Method for preparing Alectinib Grant 10,221,155 - Xu | 2019-03-05 |
| AZD9291 intermediate and preparation method therefor Grant 10,167,275 - Xu J | 2019-01-01 |
| Preparation method of rociletinib Grant 10,138,224 - Xu Nov | 2018-11-27 |
| Preparation Method of Cobimetinib App 20180273506 - XU; Xuenong | 2018-09-27 |
| Preparation Method of Rociletinib App 20180230133 - XU; Xuenong | 2018-08-16 |
| Preparation method for antitumor drug AP26113 Grant 10,039,775 - Xu August 7, 2 | 2018-08-07 |
| Ribociclib intermediate and preparation method therefor Grant 10,005,726 - Xu June 26, 2 | 2018-06-26 |
| Method for preparing Palbociclib Grant 10,005,778 - Xu June 26, 2 | 2018-06-26 |
| Preparation method for Bemaciclb Grant 9,969,718 - Xu May 15, 2 | 2018-05-15 |
| Ribociclib Intermediate And Preparation Method Therefor App 20180093950 - XU; Xuenong | 2018-04-05 |
| Azd9291 Intermediate And Preparation Method Therefor App 20180072706 - XU; Xuenong | 2018-03-15 |
| Preparation Method For Antitumor Drug Ap26113 App 20180071324 - XU; Xuenong | 2018-03-15 |
| Preparation method of Nintedanib Grant 9,856,215 - Xu January 2, 2 | 2018-01-02 |
| Method for preparing Palbociclib Grant 9,850,244 - Xu December 26, 2 | 2017-12-26 |
| Method for preparing Afatinib and intermediate thereof Grant 9,845,315 - Xu December 19, 2 | 2017-12-19 |
| Preparation Method For Bemaciclb App 20170305884 - Xu; Xuenong | 2017-10-26 |
| Method For Preparing Palbociclib App 20170247380 - XU; Xuenong | 2017-08-31 |
| Method For Preparing Palbociclib App 20170247379 - XU; Xuenong | 2017-08-31 |
| Method For Preparing Alectinib App 20170247352 - Xu; Xuenong | 2017-08-31 |
| Method for preparing volasertib and intermediate thereof Grant 9,688,685 - Xu June 27, 2 | 2017-06-27 |
| Preparation Method Of Nintedanib App 20170174625 - XU; Xuenong | 2017-06-22 |
| Preparation method of ticagrelor and intermediates thereof Grant 9,604,991 - Xu March 28, 2 | 2017-03-28 |
| Method for preparing Ibrutinib Grant 9,598,425 - Xu March 21, 2 | 2017-03-21 |
| Method for Preparing Volasertib and Intermediate thereof App 20170073350 - XU; Xuenong | 2017-03-16 |
| Avanafil preparation method Grant 9,593,101 - Xu March 14, 2 | 2017-03-14 |
| Avanafil Preparation Method App 20160362400 - Xu; Xuenong | 2016-12-15 |
| Method for preparing nilotinib intermediate App 20160311777 - Xu; Xuenong ; et al. | 2016-10-27 |
| Avanafil preparation method Grant 9,453,001 - Xu September 27, 2 | 2016-09-27 |
| Method for Preparing Ibrutinib App 20160264584 - Xu; Xuenong | 2016-09-15 |
| Preparation method of Ticagrelor and intermediates thereof App 20160102101 - Xu; Xuenong | 2016-04-14 |
| Method For Preparing Afatinib And Intermediate Thereof App 20160083373 - Xu; Xuenong | 2016-03-24 |
| Avanafil Preparation Method App 20160075693 - Xu; Xuenong | 2016-03-17 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 